Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M S BARTLETT

Showing results (301-310 of 386) with videos related to

Pageof 39
Sort By:
Breast Cancer Research and Treatment|July 29, 2011
Co-expression of SNAIL and TWIST determines prognosis in estrogen receptor-positive early breast cancer patientsJohanna G H van Nes, Esther M de Kruijf, Hein Putter, et al.
The Lancet. Oncology|January 19, 2010
Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601)John M S Bartlett, Alison F Munro, Janet A Dunn, et al.
Breast Cancer Research and Treatment|November 28, 2017
Evaluation of applying IHC4 as a prognostic model in the translational study of Intergroup Exemestane Study (IES): PathIESM C U Cheang, J M Bliss, G Viale, et al.
Breast Cancer Research : BCR|July 10, 2010
Mammostrat as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapyJohn M S Bartlett, Jeremy Thomas, Douglas T Ross, et al.
Health Technology Assessment (Winchester, England)|February 12, 2016
OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancerRobert C Stein, Janet A Dunn, John M S Bartlett, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 12, 2024
Validation of the Prognostic Performance of Breast Cancer Index in Hormone Receptor-Positive Postmenopausal Breast Cancer Patients in the TEAM TrialJohn M S Bartlett, Keying Xu, Jenna Wong, et al.
NPJ Breast Cancer|June 27, 2017
Molecular stratification of early breast cancer identifies drug targets to drive stratified medicineJane Bayani, Cindy Q Yao, Mary Anne Quintayo, et al.
British Journal of Cancer|October 15, 2014
Time dependence of biomarkers: non-proportional effects of immunohistochemical panels predicting relapse risk in early breast cancerJ Stephen, G Murray, D A Cameron, et al.
European Journal of Cancer (Oxford, England : 1990)|May 12, 2017
HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2John M S Bartlett, Ikhlaaq Ahmed, Meredith M Regan, et al.
Oncotarget|May 11, 2017
Pancreatic cancer ascites xenograft-an expeditious model mirroring advanced therapeutic resistant diseaseTalia Golan, Chani Stossel, Michael Schvimer, et al.
Pageof 39

Showing results (301-310 of 386) with videos related to

Sort By:
Pageof 39
Breast Cancer Research and Treatment|July 29, 2011
Co-expression of SNAIL and TWIST determines prognosis in estrogen receptor-positive early breast cancer patientsJohanna G H van Nes, Esther M de Kruijf, Hein Putter, et al.
The Lancet. Oncology|January 19, 2010
Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601)John M S Bartlett, Alison F Munro, Janet A Dunn, et al.
Breast Cancer Research and Treatment|November 28, 2017
Evaluation of applying IHC4 as a prognostic model in the translational study of Intergroup Exemestane Study (IES): PathIESM C U Cheang, J M Bliss, G Viale, et al.
Breast Cancer Research : BCR|July 10, 2010
Mammostrat as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapyJohn M S Bartlett, Jeremy Thomas, Douglas T Ross, et al.
Health Technology Assessment (Winchester, England)|February 12, 2016
OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancerRobert C Stein, Janet A Dunn, John M S Bartlett, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 12, 2024
Validation of the Prognostic Performance of Breast Cancer Index in Hormone Receptor-Positive Postmenopausal Breast Cancer Patients in the TEAM TrialJohn M S Bartlett, Keying Xu, Jenna Wong, et al.
NPJ Breast Cancer|June 27, 2017
Molecular stratification of early breast cancer identifies drug targets to drive stratified medicineJane Bayani, Cindy Q Yao, Mary Anne Quintayo, et al.
British Journal of Cancer|October 15, 2014
Time dependence of biomarkers: non-proportional effects of immunohistochemical panels predicting relapse risk in early breast cancerJ Stephen, G Murray, D A Cameron, et al.
European Journal of Cancer (Oxford, England : 1990)|May 12, 2017
HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2John M S Bartlett, Ikhlaaq Ahmed, Meredith M Regan, et al.
Oncotarget|May 11, 2017
Pancreatic cancer ascites xenograft-an expeditious model mirroring advanced therapeutic resistant diseaseTalia Golan, Chani Stossel, Michael Schvimer, et al.
Pageof 39